aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Tome Biosciences, founded with a core mission to revolutionize genome editing, specializes in programmable gene insertion technology. Leveraging CRISPR, the company enables precise insertion of any genetic sequence of any size at any location within a genome. Their innovative approach aims to advance therapeutic applications and research, focusing on providing cutting-edge solutions for genetic disorders and other medical conditions.
Notable figures associated with Tome Biosciences include leading experts in biotechnology and genetic engineering. The company has secured significant investments from prominent venture capital firms, underscoring its potential and credibility in the biotech industry. Key achievements include breakthroughs in CRISPR-based gene editing techniques, positioning Tome Biosciences as a pivotal player in the field of genomic medicine. Their work promises to have a profound impact on the treatment of genetic diseases and the future of personalized medicine.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Gene Editing
Technology
Biotech, Crispr
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Tome Biosciences founded?
Tome Biosciences was founded in 2021.
Where is Tome Biosciences's headquarters located?
Tome Biosciences's headquarters is located in Watertown, MA, US.
When was Tome Biosciences's last funding round?
Tome Biosciences's most recent funding round was for $213M (USD) in December 2023.
How many employees does Tome Biosciences have?
Tome Biosciences has 88 employees as of Feb 4, 2024.
How much has Tome Biosciences raised to-date?
As of July 05, 2023, Tome Biosciences has raised a total of $213M (USD) since Dec 12, 2023.
Add Comparison
Total Raised to Date
$213M
USD
Last Update Dec 12, 2023
Last Deal Details
$213M
USD
Dec 12, 2023
Series A
Total Employees Over Time
88
As of Feb 2024
Tome Biosciences Address
Watertown,
Massachusetts
02472
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts